Success Metrics

Clinical Success Rate
83.3%

Based on 10 completed trials

Completion Rate
83%(10/12)
Active Trials
5(28%)
Results Posted
110%(11 trials)
Terminated
2(11%)

Phase Distribution

Ph phase_4
2
11%
Ph phase_3
11
61%
Ph phase_2
2
11%
Ph not_applicable
2
11%

Phase Distribution

0

Early Stage

2

Mid Stage

13

Late Stage

Phase Distribution17 total trials
Phase 2Efficacy & side effects
2(11.8%)
Phase 3Large-scale testing
11(64.7%)
Phase 4Post-market surveillance
2(11.8%)
N/ANon-phased studies
2(11.8%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

83.3%

10 of 12 finished

Non-Completion Rate

16.7%

2 ended early

Currently Active

5

trials recruiting

Total Trials

18

all time

Status Distribution
Active(6)
Completed(10)
Terminated(2)

Detailed Status

Completed10
Recruiting5
Terminated2
Not yet recruiting1

Development Timeline

Analytics

Development Status

Total Trials
18
Active
5
Success Rate
83.3%
Most Advanced
Phase 4

Trials by Phase

Phase 22 (11.8%)
Phase 311 (64.7%)
Phase 42 (11.8%)
N/A2 (11.8%)

Trials by Status

recruiting528%
completed1056%
terminated211%
not_yet_recruiting16%

Recent Activity

Clinical Trials (18)

Showing 18 of 18 trials
NCT06094010Phase 3

A Surveillance Study of Susceptibility to Baloxavir Marboxil in Pediatric Participants With Influenza and Transmission of Influenza to Household Contacts

Recruiting
NCT06653569Phase 3

Efficacy of Baloxavir Against Influenza in Hospitalized Patients: The INFLUENT Study (INpatients inFLUENza Treatment)

Recruiting
NCT06774859Phase 3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Chinese Pediatric Participants 1 to <12 Years of Age With Influenza Symptoms

Completed
NCT04381936Phase 3

Randomised Evaluation of COVID-19 Therapy

Recruiting
NCT04712539Phase 2

Baloxavir and Oseltamivir for the Treatment of Severe Influenza Infection in Immunocompromised Patients

Recruiting
NCT06161454Phase 4

Xofluza-Wearables Feasibility-Study

Completed
NCT03969212Phase 3

Study to Assess the Efficacy of Baloxavir Marboxil Versus Placebo to Reduce Onward Transmission of Influenza A or B in Households

Completed
NCT06207058

Evaluation of a Screen and Treat Protocol for Influenza

Terminated
NCT05170009Phase 2

Baloxavir in Combination With Oseltamivir in Allogenic Bone Marrow Transplant Recipients With Influenza

Terminated
NCT06762587Not Applicable

Oseltamivir and Baloxavir Marboxil for Prophylaxis Against Influenza Under a Hospital-based Setting

Not Yet Recruiting
NCT02735707Phase 3

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

Recruiting
NCT03653364Phase 3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants From Birth to < 1 Year With Influenza-Like Symptoms

Completed
NCT04141930Phase 4

Pilot of Cohort of Households for Influenza Monitoring and Evaluation in Seattle

Completed
NCT03684044Phase 3

Study to Assess Efficacy and Safety of Baloxavir Marboxil In Combination With Standard-of-Care Neuraminidase Inhibitor In Hospitalized Participants With Severe Influenza

Completed
NCT03959332Not Applicable

Study to Assess the Pharmacokinetics, Safety and Tolerability of Baloxavir Marboxil in Healthy Chinese Participants

Completed
NCT03629184Phase 3

Study to Assess the Safety, Pharmacokinetics, and Efficacy of Baloxavir Marboxil in Healthy Pediatric Participants With Influenza-Like Symptoms

Completed
NCT02949011Phase 3

Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Patients With Influenza at High Risk of Influenza Complications

Completed
NCT02954354Phase 3

A Study of S-033188 (Baloxavir Marboxil) Compared With Placebo or Oseltamivir in Otherwise Healthy Patients With Influenza

Completed

All 18 trials loaded

Drug Details

Intervention Type
DRUG
Total Trials
18